Comparative efficacy of intravenous cyclophosphamide, mycophenolate mofetil, and tacrolimus as induction therapy for lupus nephritis: A randomized controlled open-label trial
Authors' conclusion
TAC was non-inferior compared to IV CYC and MMF for LN as induction therapy, with a comparable safety profile during the study period.
Study context
- Population
- Children and adults aged ≥10 years with clinical or biopsy-proven lupus nephritis (LN)94% females
- Participants
- 82 children
- Comparison
- IV CYC vs mycophenolate mofetil (MMF) vs tacrolimus (TAC) as induction therapy for LN
- IV CYCn = 28reference
- MMFn = 27
- TACn = 27
- Primary endpoint
- Proportion achieving renal response (CR or partial (PR))
- Follow-up
- Week 24
Methodological detailsopen-label, non-inferiority, active-controlled, three-arm
- Open-label
- Non-inferiority
- Active-controlled
- Three-arm
Primary result
As reported in the abstract
Renal response (CR or PR) · 24 weeks
P = 0.58
Secondary outcomes
Events
| Outcome | IV CYC | TAC |
|---|---|---|
| Deaths due to serious infections | 3 | 1 |
Serum CXCL10 post-treatment
- Reduced significantly post-treatment in all three groups
- P < 0.001
Original publication
Comparative efficacy of intravenous cyclophosphamide, mycophenolate mofetil, and tacrolimus as induction therapy for lupus nephritis: A randomized controlled open-label trial. Lupus. Published 14 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →